In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Population screening for sudden cardiac death in young people is feasible with a basic screening programme

Low referral rate, but a small number of lethal pathologies likely to be detected

Risk Factors and Prevention

Amsterdam, 8 May 2014.  Despite fears over cost, the wide-scale screening of young people to detect risk of sudden cardiac death (SCD) is feasible and cost effective, according to a study presented at EuroPRevent 2014.(1) More than 12,000 people aged between 14 and 35 were screened at a cost of £35 (40 euro) each; rates of subsequent referral for further investigation were low and considered of "a relative low additional cost" to health services.

The study was reported today at the EuroPRevent congress 2014 in Amsterdam by Dr Rajay Narain, Clinical Research Fellow from the Department of Cardiovascular Sciences, St George's University of London (and Cardiac Risk in the Young Heart Screening Charity), UK.

As background to the study Dr Narain explained that the most publicised cases of SCD in young people occur in elite sports players and athletes. Yet the majority of cases occur as a result of inherited cardiac conditions (such as hypertrophic cardiomyopathy), and a large proportion of these, he adds, can be detected during life. SCD in a young person is likely to have resulted from an arrhythmia caused by a mutation in one of the cardiac ion channels or from other inherited conditions affecting the muscles of the heart.

"To prevent such tragedies," said Dr Narain, "sporting and scientific bodies recommend pre-participation screening in young athletes. However, this approach is controversial because of cost - and most SCDs in the young are likely to occur in non-competitive athletes. It was thus our aim to see if population screening was feasible in this age group."

The study involved the screening of 12,000 young people irrespective of their athletic ability. Only 13% were considered elite athletes. Screening was performed at a cost of £35 per individual and comprised a health questionnaire, 12-lead ECG and consultation with a cardiologist. Those with abnormalities had an echocardiogram on the day or were referred for further evaluation. Follow-up data were obtained through self-reported patient questionnaires.

Results showed that almost one-in-ten of the population  (9.4%) were sent for echocardiography on the day, and 2.7% (323 individuals) were referred for further assessment. Of these who responded to the questionnaire and completed their follow-up investigations (189), a cardiac pathology (or findings necessitating regular follow-up) were identified in 31 (16%). The most common were heart block (10), irregular heart rhythm (9) and valvular heart disease (6). Different cardiomyopathies were evident in 11 cases.

These pathologies were identified following an average of 1.6 further investigations, which included echo, 24-hour ECG and exercise testing.

Commenting on the results, Dr Narain said that the concept of early identification of potential victims is still a highly controversial issue. "Those opposed question the cost effectiveness of pre-participation screening and the need for multiple investigations to identify so many disease processes implicated in sudden cardiac death," he said, adding that there are also concerns about the medical and legal implications of false positive and negative results.

  
However, by applying such a screening programme as the one investigated here, Dr Nairn said that many of the sudden deaths from these conditions, which number around 15 per week in the UK, can be prevented.
  

"Fortunately," said Dr Narain, "the incidence of SCD, especially in people doing sports, is low, so several thousand athletes have to be assessed to identify the one who might die suddenly. But despite their rarity, such events are highly visible, particularly when high-profile athletes are involved. The cardiac arrest of the footballer Fabrice Muamba last year is just one example of the societal impact of such tragedies."

Population screening to prevent SCD in young people is "possible and achievable" said Dr Narain, who added: "Most developed countries have the potential for creating an infrastructure in high schools similar to established immunisation programmes. There is evidence that teachers, coaches and even volunteering parents could be trained in ECGs. The incentive is prudent - 25–30% of the population in the Western world is now aged 18 or under."

References

1. Narain R, Dhutia H, Merghani A, et al. Preventing sudden cardiac death in the young: Results form a population-based screening program in the UK. Please see the details of the session here. The abstract can be found in the press kit on site or should be requested at press@escardio.org

Notes to editor

Did you want to tweet about our congress? - if you do, please use the official #Europrevent hashtag! Thank you

About EuroPrevent
EuroPrevent is the annual congress of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR), an association of the European Society of Cardiology (ESC).

About the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)
The European Association for Cardiovascular Prevention & Rehabilitation (EACPR) is a registered branch of the ESC. Its aim is to promote excellence in research, practice, education and policy in cardiovascular prevention and rehabilitation in Europe.

About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean.  Its mission is to reduce the burden of cardiovascular disease in Europe.

Information for journalists attending EuroPRevent 2014

  • If you have any question or request regarding interview opportunities, please contact:
    ESC Press Office
    Alice Prieto
    press@escardio.org
    Tel: +336 22 41 84 92 (off site support number)
  • EuroPRevent 2014 takes place in Amsterdam, the Netherlands, on 8-10 May 2014 at the Rai Congress Center. 
  • Look here for the current programme at a glance.
  • For full details of a session, have a look at the Scientific Programme & Planner.
  • On-site Press registration process:
    • Free registration applies to press representatives upon receipt of valid credentials and a fully completed embargo form.
    • Credential: either your ID press card or letter of assignment with proof of 3 published articles
    • Press registration is not available to Industry or its Public Relations representatives, event management, marketing or communications representatives
    • The decision of the ESC Press Office is final regarding all press registration requests.
    • When your registration as press will be validated you will be given a press badge and the press kit.